Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes

被引：29

作者：

Barzon, Luisa ^{[1
,2
]}

Squarzon, Laura ^{[1
]}

Masiero, Serena ^{[1
]}

Pacenti, Monia ^{[2
]}

Marcati, Giorgia ^{[2
]}

Mantelli, Barbara ^{[1
]}

Gabrielli, Liliana ^{[3
]}

Pascucci, Maria Grazia ^{[4
]}

Lazzarotto, Tiziana ^{[3
,5
]}

Caputo, Antonella ^{[1
,2
]}

Palu, Giorgio ^{[1
,2
]}

机构：

[1] Univ Padua, Dept Mol Med, I-35121 Padua, Italy

[2] Padova Univ Hosp, Clin Microbiol & Virol Unit, Padua, Italy

[3] St Orsola Malpighi Univ Hosp, Operat Unit Clin Microbiol, Bologna, Italy

[4] Direz Gen Sanita & Polit Sociali, Serv Sanita & Pubbl, Bologna, Italy

[5] Univ Bologna, Dept Specialized Expt & Diagnost Med, I-40126 Bologna, Italy

来源：

VACCINE | 2014年 / 32卷 / 41期

关键词：

Bivalent HPV vaccine; Quadrivalent HPV vaccine; HPV16; HPV18; HPV31; HPV45; Neutralizing antibody; Cross-neutralizing antibody; Pseudovirion-based neutralization assay; Cervical cancer prevention; HPV-16/18 AS04-ADJUVANTED VACCINE; OF-STUDY ANALYSIS; HPV TYPES; HPV-6/11/16/18; VACCINE; (HPV)-16/18 VACCINE; PROTECTIVE EFFICACY; PARTICLE VACCINE; FOLLOW-UP; IMMUNOGENICITY; WOMEN;

D O I：

10.1016/j.vaccine.2014.07.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Aim of this investigator-initiated study was to evaluate and compare the titres of neutralizing and cross-neutralizing antibodies (NAbs) induced by the bivalent (Cervarix (R)) and quadrivalent (Gardasil (R)) HPV vaccines in a cohort of girls aged 11-13 years from organized vaccination programmes. To this aim, HPV16 and HPV18 NAbs were measured by pseudovirion-based neutralization assays in serum collected at 1-6 months after the third vaccine dose in 107 girls vaccinated with Cervarix (R) and 126 vaccinated with Gardasil (R), while HPV31 and HPV45 cross-NAbs were tested in the first 50 consecutive girls of both vaccine groups. The results of this study demonstrated that all vaccinated girls developed HPV16 and HPV18 NAbs, with the exception of two Gardasil (R) vaccinees with undetectable HPV18 NAbs. Geometric mean titres (GMTs) of both HPV16 and HPV18 NAbs were significantly higher in Cervarix (R) than in Gardasil (R) vaccinees [HPV16 NAb GMT 22,136 (95% CI, 18,811-26,073) vs 5092 (4230-6151), respectively; P < 0.0001; HPV18 NAb GMT 11,962(9536-14,363) vs 1804(1574-2110), respectively; P < 0.0001]. Cross-NAbs to HPV31 and HPV45 were detected more frequently Cervarix (R) (HPV31 NAb positivity rates 92.7% and 36%, respectively; P < 0.05) than in Gardasil (R) vaccinees (HPV45 NAb positivity rates 56% and 6%, respectively; P < 0.0001). The titres of cross-NAbs against HPV31 and HPV45 were also significantly higher in Cervarix (R) than in Gardasil (R) vaccinees [HPV31 NAb GMT 157.2(95% CI, 92-269) vs 13.0(6.5-25.8), respectively; P < 0.0001; HPV45 NAb GMT 4.7 (2.1-10.2) vs 1.3 (0.3-3.1), respectively; P < 0.01]. In conclusion, in adolescent girls vaccinated within organized vaccination programmes, HPV vaccines drive the generation not only of NAbs to HPV vaccine types, but also of cross-NAbs. The bivalent vaccine induced significantly higher HPV16 and HPV18 NAb titres and more frequently and at higher titre HPV31 and HPV45 cross-NAbs than the quadrivalent vaccine. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：5357 / 5362

页数：6

共 37 条

[1]

[Anonymous], 2009, HUMAN PAPILLOMAVIRUS

[2] A review of human carcinogens-Part B: biological agents [J].

Bouvard, Veronique ;

Baan, Robert ;

Straif, Kurt ;

Grosse, Yann ;

Secretan, Beatrice ;

El Ghissassi, Fatiha ;

Benbrahim-Tallaa, Lamia ;

Guha, Neela ;

Freeman, Crystal ;

Galichet, Laurent ;

Cogliano, Vincent .

LANCET ONCOLOGY, 2009, 10 (04) :321-322

[3] The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years [J].

Brown, Darron R. ;

Kjaer, Susanne K. ;

Sigurdsson, Kristjan ;

Iversen, Ole-Erik ;

Hernandez-Avila, Mauricio ;

Wheeler, Cosette M. ;

Perez, Gonzalo ;

Koutsky, Laura A. ;

Tay, Eng Hseon ;

Garcia, Patricia ;

Ault, Kevin A. ;

Garland, Suzanne M. ;

Leodolter, Sepp ;

Olsson, Sven-Eric ;

Tang, Grace W. K. ;

Ferris, Daron G. ;

Paavonen, Jorma ;

Steben, Marc ;

Bosch, F. Xavier ;

Dillner, Joakim ;

Joura, Elmar A. ;

Kurman, Robert J. ;

Majewski, Slawomir ;

Munoz, Nubia ;

Myers, Evan R. ;

Villa, Luisa L. ;

Taddeo, Frank J. ;

Roberts, Christine ;

Tadesse, Amha ;

Bryan, Janine ;

Lupinacci, Lisa C. ;

Giacoletti, Katherine E. D. ;

Sings, Heather L. ;

James, Margaret ;

Hesley, Teresa M. ;

Barra, Eliav .

JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07) :926-935

[4] End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age [J].

Castellsague, X. ;

Munoz, N. ;

Pitisuttithum, P. ;

Ferris, D. ;

Monsonego, J. ;

Ault, K. ;

Luna, J. ;

Myers, E. ;

Mallary, S. ;

Bautista, O. M. ;

Bryan, J. ;

Vuocolo, S. ;

Haupt, R. M. ;

Saah, A. .

BRITISH JOURNAL OF CANCER, 2011, 105 (01) :28-37

[5] In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection [J].

Day, Patricia M. ;

Kines, Rhonda C. ;

Thompson, Cynthia D. ;

Jagu, Subhashini ;

Roden, Richard B. ;

Lowy, Douglas R. ;

Schiller, John T. .

CELL HOST & MICROBE, 2010, 8 (03) :260-270

[6] Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women A Randomized Clinical Trial [J].

Dobson, Simon R. M. ;

McNeil, Shelly ;

Dionne, Marc ;

Dawar, Meena ;

Ogilvie, Gina ;

Krajden, Mel ;

Sauvageau, Chantal ;

Scheifele, David W. ;

Kollmann, Tobias R. ;

Halperin, Scott A. ;

Langley, Joanne M. ;

Bettinger, Julie A. ;

Singer, Joel ;

Money, Deborah ;

Miller, Dianne ;

Naus, Monika ;

Marra, Fawziah ;

Young, Eric .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (17) :1793-1802

[7] A Randomized, Observer-Blinded Immunogenicity Trial of Cervarix® and Gardasil® Human Papillomavirus Vaccines in 12-15 Year Old Girls [J].

Draper, Eve ;

Bissett, Sara L. ;

Howell-Jones, Rebecca ;

Waight, Pauline ;

Soldan, Kate ;

Jit, Mark ;

Andrews, Nicholas ;

Miller, Elizabeth ;

Beddows, Simon .

PLOS ONE, 2013, 8 (05)

[8] Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera [J].

Draper, Eve ;

Bissett, Sara L. ;

Howell-Jones, Rebecca ;

Edwards, Debbie ;

Munslow, Graham ;

Soldan, Kate ;

Beddows, Simon .

VACCINE, 2011, 29 (47) :8585-8590

[9] Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years [J].

Einstein, Mark H. ;

Baron, Mira ;

Levin, Myron J. ;

Chatterjee, Archana ;

Fox, Bradley ;

Scholar, Sofia ;

Rosen, Jeffrey ;

Chakhtoura, Nahida ;

Lebacq, Marie ;

van der Most, Robbert ;

Moris, Philippe ;

Giannini, Sandra L. ;

Schuind, Anne ;

Datta, Sanjoy K. ;

Descamps, Dominique .

HUMAN VACCINES, 2011, 7 (12) :1359-1373

[10] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years [J].

Einstein, Mark H. ;

Baron, Mira ;

Levin, Myron J. ;

Chatterjee, Archana ;

Fox, Bradley ;

Scholar, Sofia ;

Rosen, Jeffrey ;

Chakhtoura, Nahida ;

Meric, Dorothee ;

Dessy, Francis J. ;

Datta, Sanjoy K. ;

Descamps, Dominique ;

Dubin, Gary .

HUMAN VACCINES, 2011, 7 (12) :1343-1358

← 1 2 3 4 →